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Thecolonicmucusbarrieristheﬁrstlineofdefencethattheunderlyingmucosahasagainstthewiderangeofpotentiallydamaging
agents of microbial, endogenous, and dietary origin that occur within the colonic lumen. The functional component of mucus
is the secreted, polymeric glycoprotein mucin. The mucus barrier can either act as an energy source or a support medium for
growth to the intestinal microﬂora. The mucus barrier appears to eﬀectively partition the vast number of microbial cells from
the underlying epithelium. The normal functionality and biochemistry of this mucus barrier appears to be lost in diseases of the
colorectal mucosa. Germ-free animal studies have highlighted the necessity of the presence of the colonic microﬂora to drive the
maturation of the colonic mucosa and normal mucus production. A number of by-products of the microﬂora have been suggested
to be key luminal drivers of colonic mucus secretion.
1.Background
The colonic mucosa is constantly exposed to a wide range
of luminal agents that have the potential for either mucosal
damage, or mucosal protection. These luminal agents can
be of microbial, dietary or endogenous origin. “Normal”
colonic transit time varies widely in humans but within
physiological boundaries would be between 24 and 48 hours,
in comparison to transit through the upper GI tract which
occurs within a few hours [1, 2]. Therefore, there is a longer
exposure time of the colonic mucosa to luminal agents
than to the underlying tissues of other areas of the gut.
In addition, due to the role of the colon in the salvage
of unabsorbed nutrients and absorption of ﬂuid [3], these
luminal agents will be concentrated (particularly in the distal
bowel), resulting in further increases of mucosal exposure to
these agents. While removal of water from the faecal bulk is
likely to reduce the diﬀusion of agents from the majority of
thefaecalcross-section,directcontactwillstilloccurbetween
the mucus and the outer surfaces of the colonic luminal
contents.
T h el a r g eb o w e la l s op l a y sh o s tt oa p p r o x i m a t e l y1 0 13
bacteria and other micro-organisms [4] and is thought to
include over 500 bacterial species [5]. As such, changes to
the prevalent species within the microﬂoral population or
to microﬂoral functioning and output within the bowel are
likely to be intimately linked with colorectal health and
disease [6]. While digestion per se does not tend to occur
in the colon, the colonic microﬂora acts to degrade dietary
ﬁbre and/or other dietary factors that escape digestion to
produce further agents that could either harm or protect the
underlying mucosa.
The colonic mucus barrier is the ﬁrst line of defence
the underlying mucosa has against the myriad of damaging
agents that occur within the colonic lumen [7]. The colonic
mucus barrier also acts to greatly reduce the shear stress
caused by the passage of the luminal bolus along the colon
[8]. This barrier can also act as an energy source or as a
niche for bacteria within the large bowel [9, 10]. Despite
the relatively high potential for luminal exposure, previous
studies in healthy humans suggest that bacteria do not
routinely associate with the colonic mucosa and only occur
at the luminal side of the intestinal mucus layer [11]. The
remainder of this paper will focus on current evidence for
how the interplay between microﬂora and mucus may be
a key factor in mucosal health and disease and will also2 International Journal of Inﬂammation
highlight what areas of research may be considered in the
future to further understanding of this topic.
2. Colonic Mucus Productionand Secretion
Mucus acts to protect most mucosal surfaces in the gut,
airways, and urinogenital tract. The main functional com-
ponent of mucus is mucin. Disulphide bridges between
cysteine-rich areas towards the C- and N-termini of the
mucin backbone act to endow mucus with its characteristic
viscoelastic gel properties. Up to 85% of the mucin molecule
is oligosaccharide side chains by weight. The terminal sugars
of these side chains are believed to play a crucial role in the
adhesion of mucins to diﬀerent bacterial cells (e.g., [12, 13]).
Changes in both the MUC gene product and glycosylation
patterns are believed to be associated with the onset or
development of colonic mucosal diseases, such as colorectal
cancer and inﬂammatory bowel disease (IBD) [14].
In humans, there are ﬁve polymeric, secretory mucin
gene products that are currently known, MUC2, MUC5AC,
MUC5B, MUC6 [15], and MUC19 [16]. These genes for
MUC2, MUC5AC, MUC5B, and MUC6 are all expressed
from the same chromosome locus (11p15.5) [17]. Through-
out the small and large intestine, MUC2 is the predominant
mucin gene product [18]. Within the mammalian colon,
mucins are highly negatively charged, due to the presence
of ester sulphate and terminal sialic acids [19]. Reduction of
this negative charge in secreted mucins is generally believed
tobeassociatedwithcolorectaldiseaseonsetandprogression
[20, 21].
Following transcription, mucin gene products are ﬁrstly
N-glycosylated and dimerise (through cysteine-rich regions
attheC-terminalofthemucinbackbone)intheroughendo-
plasmic reticulum [22]. This N-glycosylation is also believed
to be important in the subsequent transfer of mucins into
the Golgi apparatus [23]. Within this compartment, mucins
are O-glycosylated [24], prior to N-terminal oligomerisation
[25]. Mucin granules are subsequently packaged tightly
due to the presence of high levels of calcium ions [26].
Recent studies in this area have noted that the granules
of the secreted gel-forming mucin MUC5B (isolated from
saliva) appeal to each contain somewhere in the region of
50–100 sub-units of mucin, organised into 10–15 isolated
polymers, which are believed to represent the grouping
of cysteine-rich C and N-terminal regions [27]. Granules
rapidly expand from a diameter of approximately 350nm
to around 1000nm, with the end products being polymeric
chains of 4–8 mucin subunits [27]. Upon their release,
mucin molecules become disassociated from the calcium
ionsandarebelievedtounfurlinthepresenceoftheaqueous
milieu.Ithaspreviouslybeensuggestedthattherheologically
thick mucus secretion seen in cystic ﬁbrosis is a result of
incomplete hydration of mucin granules, possibly as a result
of defective HCO3
− transport [28, 29].
The pathways associated with mucus production are
highlighted in Figure 1. Triggering of mucin synthesis or
secretion, alongside goblet cell/epithelial proliferation and
crypt lengthening, may be mediated by a spectrum of
neurohumoral, local, and immune factors. Total mucin
output from the colon can be elevated as a result of increased
mucin biosynthesis, exocytosis rates, and total goblet cell
numbers.
Increased MUC2 mRNA was noted by quantitative RT-
PCR analysis in human colon cancer cell lines in response
to a single stimulation with IL-4 (approximate two-fold
increaseincomparisontobaseline),IL-13,andTNF-α(c.2.5-
fold increase in MUC2 mRNA) via MAP kinase pathways
[30]. N-glycosylation of MUC2 monomers appears to be
necessary to drive further processing of mucin subunits, and
is a required step prior to passing into the Golgi apparatus
[23]. The expression of mRNA of 3 out of 8 tested isoen-
zymes governing O-glycosylation of mucins (polypeptide N-
acetylgalactosaminyltransferases) in a colon cancer cell line,
was also noted to be upregulated by the Th2 cytokine IL-4,
resultinginincreasedincorporationofGalNAcintomucino-
glycans[31].Withinarandommutagenesismodelofmurine
colitis, an increase in both the amounts of Th1 and Th2
cytokines secreted by cultured leukocytes and the increased
leukocyte numbers within mesenteric lymph nodes were
associated with the accumulation of an unglycosylated Muc2
oligomers precursor in the Golgi apparatus. Within the same
study, unglycosylated MUC2 precursors were also noted
to occur in human ulcerative colitis, even in noninﬂamed
intestinal tissue [32]. In Il-10-deﬁcient mice, total Muc2
output and synthesis was reduced in germ-free animals.
Upon application of a commensal microﬂora, there was
a signiﬁcant reduction in mucin sulphation compared to
sulphation in the germ-free animal [33]. This evidence
would therefore suggest a major role for Th2 cytokines in the
control of mucin synthesis.
In studies on isolated colonic crypts from macroscopi-
cally normal tissues, it was noted that goblet cell exocytosis,
as assessed by diﬀerential interference contrast microscopy,
occurred during cholinergic and histamine-mediated stim-
ulation [34]. Within these studies, prostaglandin E2 stim-
ulation did not aﬀect mucin exocytosis from goblet cells
but appeared to drive ﬂuid loss from columnar cells, which
is likely to “wash-out” mucins from the crypts to rest on
the luminal surface of the epithelium. Studies on total
mucin output from an isolated, vascularly perfused rat
colon have noted an increase in the number of cavitated
goblet cells following stimulation with cholinergic agonists,
prostaglandin E2, and peptide YY [35]. In further studies
using this model, total mucin output (as assessed by ELISA)
was also increased in response to the agents used in the
previous study [35] as well as serotonin, Vasoactive Intestinal
Peptide (VIP), interleukin-1β, and NO precursors [36].
While it is not possible to isolate the eﬀect of these factors
on, for example, mucin biosynthesis or granular exocytosis
within such studies, these data give a strong physiological
indicator of drives for increased colonic mucin discharge.
While mostly associated with goblet cell proliferation
in the lung, recent studies have suggested a role for the
ETS transcription factor SPDEF in intestinal goblet cell
proliferation [37, 38]. Similarly, IL-9 has been linked to
the lung inﬂammatory pathologies. In IL-9-overexpressing
mice, Muc2 expression (as well as other goblet cell-related












Figure 1: Major posttranscriptional steps involved in colonic mucin synthesis and secretion. (1) MUC gene products are translated at the
rough endoplasmic reticulum. (2) MUC gene products are then N-glycosylated and dimerised at the C-terminal. (3) The N-glycosylation is
necessary for mucins to be transferred to the Golgi apparatus for further processing. Within the Golgi apparatus, mucins are O-glycosylated
and polymerised by disulphide bridge formation between cysteine-rich N-terminal sections of the polypeptide backbone. Polymeric mucins
become tightly packed due to the presence of high concentrations of calcium ions. (4) The resulting mucin granules are externalised by the
goblet cells via exocytosis. (5) Following release, mucin granules rapidly unfurl into a viscoelastic mucus gel bilayer (adapted from details
given in [23, 45, 46]).
studies suggested a necessity for the presence of IL-13 for this
hypersecretion and goblet cell hyperplasia to occur [39].
In vivo studies would suggest that the colonic mucus
barrier is a functional bilayer [8, 40]. The two layers are
rheologically distinct [41]. Upon the application of shear
stress, the outer layer of mucus rapidly moves from a gel
state to a liquid state. This layer is therefore believed to act
as a lubricant and is important in reducing colonic shear
stress. As it is constantly removed, this outer layer may also
act to return the material back into the centre of the lumen,
thereby aiding in the reduction of mucosal exposure to such
material [7]. The inner, adherent mucus cannot be removed
by suction and is believed to act as a selective physical barrier
tothecontactofluminalfactorswiththeunderlyingmucosa,
while still allowing absorptive function to occur [42]. Due
to the large hydration spheres of mucins in the hydrated
mucus gel, it is likely that the mucus gel is imbued with a
functional pore size anywhere in the region of 10–500nm
[43]. Diﬀusion through these pores will be dependent on
the charge of the secreted mucins and the properties of
the particle crossing the mucus, as well as the thickness of
the mucus layer. Studies assessing the secretion dynamics
of these mucus layers in an anaesthetised rat model would
suggest that the outer, lubricative mucus layer equilibrates to
maximal thicknesses of over 600μm, and the shear-resistant
inner layer is maintained at approximately 100–200μmi n
rats fed a standard diet [8, 40, 44]. It must be noted that
within these studies, the mucus layer is measured in the
absence of normal colonic contents.
3. The Colonic Mucus Barrieras
aM ic r o b ialN ic h e
The colonic mucus barrier can act as either an energy source,
or as a potential support media for growth to the colonic
microﬂora [47]. While a single bacterial species may not
possess the necessary enzymes to cleave all the chemical
linkages within the mucin structure, it has previously been
hypothesised that the ability of each species to thrive as
a whole may be dependent on the presence of upstream
degradation of mucin by the colonic microbiome. Previous
faecal culture studies under anaerobic conditions in mucin-
agar gels could suggest that enterobacteria and Bacteroides
species could be the most predominant within the colonic
mucus [48]. However, it must be noted that these studies
used gastric mucin as a starting point which has diﬀerent
carbohydrate structures than colonic mucin, which would be
expected to aﬀect both bacterial adhesion and degradation.
Due to their proximity to the underlying mucosa, it
is likely that the bacteria that populate the colonic mucus4 International Journal of Inﬂammation
barrier will have the greatest eﬀect on colonic mucosal
responses, including mucus secretion, immunity, and
inﬂammatory responses. However, very little is known
about the types of bacteria that inhabit the mucus barrier.
Recently, a series of experiments outlined by Johansson et al.,
(2008) [49] have moved the research in this area forwards.
Perhaps the major ﬁnding of this work was that within the
normal mouse colonic mucus bilayer, bacteria were only
found to occur within the outer, lubricative layer and did
not occur within the inner adherent layer (as evidenced
by 16s ribosomal RNA in situ hybridisation of histological
sections). This would therefore suggest that under normal
conditions, the adherent layer is impenetrable to colonic
bacteria and that the outer layer could be a major habitat for
commensal bacteria.
W h i l ec o l o n i cm u c u sa c t sa sb o t hab a r r i e ra n da
potential niche for the microﬂora to exploit, it also appears
as if the presence of bacteria in the colon is a major drive of
both mucus secretion and normal colonic morphology. This
is highlighted by the classic histological observation that
germ-free animals have a thinner colonic musculature, with
shorter colonic crypts alongside a lack of goblet cells and
thin mucus layer [50–53]. In normal human development,
the colonic microﬂora begins to develop from parturition
due to indirect maternal inoculation [3]. While germ-free
conditions are unlikely in either human physiology or
pathophysiology, large-scale changes to bacterial numbers
or content could greatly aﬀect mucosal protection. In the
case of an already deﬁcient mucus layer, increasing numbers
of bacteria that are able to degrade proteins would be more
likely to cause mucosal damage/inﬁltration. Temporary re-
duction of colonic bacterial numbers (e.g., during antibiotic
therapy) would be unlikely to cause unwanted mucosal side
eﬀects, but in the long term could lead to a less protective
mucus barrier.
Studies in knock-out mice have suggested that deletion
of the murine MUC2 orthologue Muc2 results in the onset
of “spontaneous” (i.e., not chemically induced) colorectal
cancer and colitis [54, 55]. Within studies on human
colorectal adenoma progression, changes to mucin gene
product expression and glycosylation patterns have been
noted. The MUC5AC gene product, which is normally
secreted in the stomach, but is absent from normal colon,
is frequently found in colorectal adenomas and in the area
surrounding the adenoma [20]. Mucinous and nonmuci-
nous carcinomas exhibit separate phenotypic changes to
mucin gene expression. In the mucinous adenocarcinoma,
there is an increased expression of both MUC5AC and
MUC2 in comparison to the nonmucinous form [56].
In the nonmucinous carcinoma, there is a reduction in
total mucus output, accompanied by a shortening of the
mucin oligosaccharide chains [21], particularly through the
increased presence of two-residue long GalNAc -sialic acids
(Sialyl-Tn antigens) [57]. The change in mucin oligosac-
charides is also characterised by a reduction in sulphation
levels versus normal mucosa [58] and reduced sialic acid
content [59]. The loss of these factors from oligosaccharides
results in the reduction of negative charge from the secreted
mucin.
Similar losses in sulphation (as well as fucosylation) have
also been noted to occur in ulcerative colitis [21, 60, 61].
A reduction in total MUC2 secretion also seems evident in
active ulcerative colitis [62, 63]. As with colorectal cancer,
there appears to be an increased expression of MUC5AC in
ulcerative colitis [64, 65], which both animal and patient
studies would suggest be linked to pre- or early neoplastic
changes [66, 67].
The above evidence highlights that changes to both the
protein and carbohydrate portions of secreted mucins occur
in the diseased state. Such changes are likely to reduce the
protective potential of the colonic mucus gel and may lead
to an altering of the available microﬂoral niche within the
secreted mucus, thereby potentially changing the bacterial
population.
Recent preliminary metabolic proﬁling studies have
suggested that an increased appearance of cysteine and
proline occur in the faecal water extracts of individuals
with colorectal cancer compared to controls [68]. Both of
these amino acids are found in high amounts in mucins
(cysteine is found in globular terminal structures and is
necessary for polymerisation whereas proline is found in
high amounts in the glycosylated variable number of tandem
repeat structures, where it is thought to act as a “spacer”
between glycosylated residues (serine or threonine) that
imbue the molecule with a greater degree of ﬂexibility). The
increased presence of these amino acids would be suggestive
of elevated mucolysis, yet would more broadly predict an
increase in protein degradation in the colorectal lumen.
Certainbacterialstrainsappeartohavetheabilitytopref-
erentially target human colonic mucins [69, 70]. Adhesion to
mucins is believed to be driven by the interaction between
external bacterial structures and mucin carbohydrate struc-
tures. Proteomic analysis of mouse colonic mucus gels
demonstrated that Fc-gamma-binding protein was found
covalently bound to isolated mucins [71].
16s ribosomal RNA analysis has previously been used
to assess global bacterial make-up of the human colonic
microﬂora[72].Insomecases,thistechnologyhasbeenused
to assess the occurrence of bacteria within mucosal biopsies
(referred to as mucosa-associated bacteria but likely to be
a mixture of any bacteria adhered to the mucosa and those
associated with the outer and inner mucus layers). Such
studies would suggest that the faecal microﬂora is distinct
from that found in mucosal biopsies, with diﬀerences
occurring in the mucosal biopsy microﬂora along the
length of the large bowel [73], with marked intra-individual
variations being also noted [74]. The mucosal biopsy
microﬂora of ulcerative colitis moving from remission to
relapse patients was noted to be considerably less stable over
time than healthy control individuals in a small cohort study
[75]. A wider diversity of the colonic biopsy TM7-bacteria
was also recently noted in Crohn’s Disease compared to
ulcerative colitis patients or controls [76].
It is possible that there is either a direct bacterial
degradation of colorectal mucins by colonic bacteria in
colorectal mucosal disease or that the presence of certain
bacterial species or by-products alters the pathways of mucin
biosynthesis and secretion. While the relative ratios ofInternational Journal of Inﬂammation 5
constituent bacterial species within the colonic microﬂora
(particularly the relative proportion of Biﬁdobacteria and
Lactobacilli) have been postulated to be of importance to
colonic health and disease [77, 78], it should be noted that
the overall enzymatic spectrum [79] of the microﬂora or
the by-products thereof [80]m a yb eo fg r e a t e rr e l e v a n c e
to human health. A number of studies have suggested that
there is an increase in the numbers of mucosa-associated
bacteria, as reviewed by Strober et al., (2007) [81], although
these levels did not necessarily appear to correlate well with
mucosal inﬂammation [82]. There is no consensus on large-
scale changes of bacterial populations or obvious mucosal
infections that occur within IBD [81]o rc o l o r e c t a lc a n c e r .
Within the case of epithelial damage and/or inﬁltration, it
is likely that bacterial contact with Toll-like receptors could
trigger inﬂammatory and immune responses, including
increased mucin secretion [83].
4. BacterialBy-Productsand
the Colonic Mucus Barrier
Althoughthecolonicmucosaissurroundedbyawidevariety
of potentially damaging agents, the physiological response
couldbedescribedasa“dampenedinﬂammation”orgeneral
tolerance. As previously discussed, an absence of colonic
microﬂora tends to result in a reduction in the standard
maturation of the colonic epithelium, as seen in atypical
histology. As very few bacteria cross the colonic epithelia
(andpossiblyeventheinneradherentmucusbarrier)outside
of major mucosal trauma, it is unlikely that bacterial
presence is having a direct eﬀect on colonic physiology until
end-stage mucosal infection. Therefore, many of the eﬀects
of bacteria on mucus secretion may be elicited indirectly by
bacterial by-products. Previous evidence from experimental
models (see below) would support this hypothesis although
it must be noted that only a fraction of bacterial by-products
have been tested for their potential to aﬀect such processes.
Upon bacterial cell death, lipopolysaccharides (LPS) are
shedintothecoloniclumen.Ingerm-freerats,colonicgoblet
cell numbers increased ﬁve days after LPS was applied orally
[84].Thelevelofinterleukin-8(IL-8)andtotalmucinmRNA
levels have also been shown to be signiﬁcantly elevated in a
mucus-producing colonic cell culture study in response to
LPS stimulation [85].
Both increased mucin release and increased goblet cell
numbers have been reported with direct instillation of low
levels of butyrate (5mM) into a vascularly perfused rat colon
model. Higher levels of butyrate (up to 100mM) actually
lowered the level of mucin secretion whereas the same
concentration range of acetate (5–100mM) increased mucin
secretion in a dose-dependent manner and propionate had
noeﬀect[86].Previousstudiesonmucussecretiondynamics
have suggested that low luminal concentrations of butyrate
(7mM) resulted in an increased rate of mucus barrier
secretion following removal, but also resulted in a decrease
in the maximal mucus thickness attained (see Figure 2)[ 87].
Similar eﬀects were noted in more recent studies where
long-term administration of high butyrate concentrations
(100mM) directly into the mouse colon over a 7-day period






























Figure 2: Rat colonic mucus secretion dynamics assessed in the
presence of 7 mM butyrate in saline (grey line) and isotonic saline
(black line). N = 5 animals for each treatment. After 60 minutes,
the loosely adherent mucus layer is removed by suction (A). Over
the subsequent 60 minutes (B), the mucus replenishment rate
was approximately three times higher in the presence of butyrate
versus the saline control (P = .0313 when compared by paired,
nonparametric t-test). Over the last hour of assessment when the
mucus barrier had reached equilibrium (C), the total maximal
mucus thickness in the presence of butyrate was signiﬁcantly lower
than the saline control group (P = .0023 when compared by
unpaired nonparametric t-test).
resulted in an upregulation of Muc2 gene expression, but
a reduction in the histologically assessed adherent mucus
layer was noted [88]. Mechanistic studies have suggested
that mucin output [89] and upregulation of MUC2 gene
expression [90] are dependent on cholinergic pathways and
myoﬁbroblast-derived prostaglandins, respectively.
Reactive oxygen species (ROSs) are a by-product of
aerobic respiration that have been shown to occur to
millimolar levels in human colonic luminal contents [91].
R O Sh a v eb e e ns h o w nt oi n c r e a s em u c u ss e c r e t i o nr a t e sa t
low luminal concentrations (5mM H2O2 in the presence of
Fe++),butleadtomucusdegradationandmucosalreddening
at higher concentrations (25 and 50mM H2O2 [42]. These
data would suggest that the presence of ROS could be
sensed by the colonic mucosa, with the low levels driving
the secretion of a more protective mucus barrier. At higher
levels, the degradation of mucus, and potential damage of
the underlying mucosa, results in degradation of the mucus
barrier that outweighs increased secretion.
5. Summary
The colonic mucus bilayer acts to reduce shear stress and
protect the underlying mucosa from damaging luminal
entities while still allowing colonic salvage to occur. As such,
the mucus barrier is a key to innate immunity. The colonic
mucus barrier represents a window of colorectal health.
There is evidence that the MUC gene products secreted
are diﬀerent in the normal state compared to colorectal
pathophysiology, such as adenoma formation and ulcerative
colitis.6 International Journal of Inﬂammation
There are uniquely high numbers of resident bacteria
within the large intestine. However, the inner layer of colonic
mucus appears to be generally impermeable to this resident
microﬂoraandmaintainsaphysicalbarrierwithanexclusion
limit of 100 microns between the overlying bacteria and
the underlying epithelium. The outer, lubricative mucus
layer appears to act as a niche for bacterial population. 16s
ribosomalRNAanalysiswouldsuggestqualitativediﬀerences
between the bacterial population that resides within the
mucus and that occurring within the lumen (approximated
by faecal sampling). It is likely that the bacteria that reside
within the mucus will have the greatest impact on the
physiology and pathophysiology of the colonic mucosa.
Development of normal colonic morphology, including
productionofafunctionallyrelevantmucusbarrier,islargely
driven by the presence of the resident colonic microﬂora. As
bacteria rarely appear to interact directly with the colonic
epitheliumundernormalphysiologicalconditions,itappears
likely that the diﬀusion of bacterial by-products across the
colonic mucus barrier to the underlying mucosa acts as a
major drive for mucosal maturation and hence aﬀects the
processes that govern mucus secretion (mucin synthesis,
mucin granule exocytosis, and goblet cell proliferation)
Previous evidence notes particular roles for LPS and SCFA
in driving mucus secretion.
There is a need for further studies into how ﬂuctuations
in speciﬁc bacterial populations aﬀect mucin synthesis and
secretion, as well as how such populations adhere to or
degrade mucus/mucins in a mixed culture. Coassessment
of faecal mucins and bacterial populations/bacterial by-
products could be utilised as a noninvasive screening tech-
nique in human participants. This methodology may be
an indirect route of testing (a) whether changes in the
microﬂora drive changes to mucin secretion/degradation
and (b) whether such changes are associated with disease
incidence or onset.
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